Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery

Carmelo Puglia, Paolo Blasi, Carmine Ostacolo, Eduardo Sommella, Claudio Bucolo, Chiara B M Platania, Giovanni L Romano, Federica Geraci, Filippo Drago, Debora Santonocito, Barbara Albertini, Pietro Campiglia, Giovanni Puglisi, Rosario Pignatello. Front Pharmacol. 2018 Mar 28;9:285.

Laboratory studyOther animalsTopical

Design

Laboratory study

Subjects

Rabbit eyes, ocular pharmacokinetic and tolerability study

Dose used in the study

PEA-loaded nanostructured lipid carriers (PEA-NLC) applied topically, compared with a PEA suspension

Duration

Not stated in the abstract

What was measured

PEA levels in ocular tissues (vitreous, retina) by liquid chromatography-tandem mass spectrometry, and ocular tolerability

What the authors reported

PEA-NLC significantly raised PEA levels in ocular tissues compared with a plain PEA suspension, with vitreous Cmax of 5919±541 pmol/g and retinal Cmax of 315±70 pmol/g. The authors describe the formulation as having high stability and strong ocular bioavailability. Ocular tolerability was assessed in rabbit eye, but the abstract does not give the result.

Limits of this study

A rabbit study of a drug-delivery formulation, not a treatment trial; it cannot show effect on retinal disease in people. Funding and conflicts not stated in the abstract.

Source

PubMed 29643808 · doi:10.3389/fphar.2018.00285

Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.